324 related articles for article (PubMed ID: 21691123)
41. Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.
Matikainen N; Taskinen MR
Curr Cardiol Rep; 2012 Dec; 14(6):721-31. PubMed ID: 22941588
[TBL] [Abstract][Full Text] [Related]
42. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.
Carmena R
Am Heart J; 2005 Nov; 150(5):859-70. PubMed ID: 16290951
[TBL] [Abstract][Full Text] [Related]
43. Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i).
Fruchart JC; Sacks FM; Hermans MP;
Curr Med Res Opin; 2010 Aug; 26(8):1793-7. PubMed ID: 20482323
[TBL] [Abstract][Full Text] [Related]
44. [Lipid management--treatment goal and strategy].
Koshiyama H
Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
[TBL] [Abstract][Full Text] [Related]
46. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
[TBL] [Abstract][Full Text] [Related]
47. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
48. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Ginsberg HN; Bonds DE; Lovato LC; Crouse JR; Elam MB; Linz PE; O'connor PJ; Leiter LA; Weiss D; Lipkin E; Fleg JL;
Am J Cardiol; 2007 Jun; 99(12A):56i-67i. PubMed ID: 17599426
[TBL] [Abstract][Full Text] [Related]
49. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.
Campbell J; Mohiuddin SM
Drugs Today (Barc); 2010 Oct; 46(10):757-64. PubMed ID: 21076712
[TBL] [Abstract][Full Text] [Related]
50. Combination lipid therapy in type 2 diabetes mellitus.
Vergès B
Expert Opin Pharmacother; 2011 Jun; 12(9):1393-403. PubMed ID: 21323502
[TBL] [Abstract][Full Text] [Related]
51. Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care.
Bestehorn K; Smolka W; Pittrow D; Schulte H; Assmann G
Curr Med Res Opin; 2010 Dec; 26(12):2833-9. PubMed ID: 21058895
[TBL] [Abstract][Full Text] [Related]
52. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Alford JC; Saseen JJ; Allen RR; Nair KV
Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
[TBL] [Abstract][Full Text] [Related]
53. Treatment of diabetic dyslipoproteinemia.
Steinmetz A
Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):239-45. PubMed ID: 12951627
[TBL] [Abstract][Full Text] [Related]
54. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
González Santos P
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
[TBL] [Abstract][Full Text] [Related]
55. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
Udawat H; Goyal RK
Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
[TBL] [Abstract][Full Text] [Related]
56. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.
Athyros VG; Mitsiou EK; Tziomalos K; Karagiannis A; Mikhailidis DP
Expert Opin Pharmacother; 2010 Apr; 11(5):723-30. PubMed ID: 20210681
[TBL] [Abstract][Full Text] [Related]
57. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.
Reasner CA
J Cardiovasc Pharmacol; 2008 Aug; 52(2):136-44. PubMed ID: 18670366
[TBL] [Abstract][Full Text] [Related]
58. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M
Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665
[TBL] [Abstract][Full Text] [Related]
59. Triglycerides: how much credit do they deserve?
Kohli P; Cannon CP
Med Clin North Am; 2012 Jan; 96(1):39-55. PubMed ID: 22391250
[TBL] [Abstract][Full Text] [Related]
60. Dyslipidemia in type 2 diabetes mellitus.
Gadi R; Samaha FF
Curr Diab Rep; 2007 Jun; 7(3):228-34. PubMed ID: 17547840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
